Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PRF1 | P14222 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4959656 | 0.90 | PTGDR2 (0.42) | PGRLMNAKDM4EALDH1A1KCNH2 | |
| SCHEMBL4102883 | 0.87 | PGR (0.44) | PGRLMNAKDM4EALDH1A1KCNH2 | |
| SCHEMBL509696 | 0.87 | PGR (0.48) | PGRLMNAKCNH2PTGDR2 | |
| SCHEMBL4104516 | 0.84 | KCNH2 (0.36) | LMNAKDM4EALDH1A1KCNH2TSHR | |
| SCHEMBL4112540 | 0.83 | PGR (0.38) | PGRLMNAKDM4EALDH1A1KCNH2 | |
| SCHEMBL4114826 | 0.82 | PGR (0.62) | PGRLMNAKDM4EALDH1A1MEN1 | |
| SCHEMBL4108592 | 0.82 | LMNA (0.40) | PGRLMNAKDM4EALDH1A1TSHR | |
| SCHEMBL4654589 | 0.81 | PGR (0.41) | PGRLMNAKDM4EALDH1A1KCNH2 | |
| SCHEMBL509240 | 0.81 | PGR (0.47) | PGRKCNH2PTGDR2 | |
| SCHEMBL508289 | 0.81 | PTGDR2 (0.41) | PGRLMNAALDH1A1KCNH2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099209-A1 | Compounds Useful in Therapy | PFIZER INC | 2009-04-16 | — | — | US | disclosed |
| US-7482375-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1874732-A1 | PYRAZOLE DERIVATIVES AS PROGESTERONE RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111856-A1 | PYRAZOLE DERIVATIVES AS PROGESTERONE RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2006-10-26 | — | — | WO | disclosed |
| US-20060241125-A1 | Compounds useful in therapy | BRADLEY PAUL A | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241125-A1 | Compounds useful in therapy | CBR3, GPER1, CBR1 | PGR 57/4885LMNA 2072/4885KDM4E 3328/4885 |
| US-20090099209-A1 | Compounds Useful in Therapy | CBR3, CBR1, GPER1 | PGR 87/4885LMNA 2314/4885KDM4E 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.